Abstract
The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have